Anebulo Pharmaceuticals, Inc. (ANEB) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Anebulo Pharmaceuticals, Inc. (ANEB) Misses Q2 EPS by 4c

 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

February 10, 2023 8:38 AM EST

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the Company or Anebulo), today announced financial results for the three months ended December 31, 2022 and recent updates.

Second Quarter Fiscal Year 2023 and Subsequent Highlights:

Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evaluating ANEB-001s potential in treating acute cannabinoid intoxication (ACI). Preliminary data showed that a single 10 mg oral dose of ANEB-001 reduced key symptoms... More